Zenas Biopharma (NASDAQ:ZBIO) Now Covered by Analysts at Wedbush

Research analysts at Wedbush assumed coverage on shares of Zenas Biopharma (NASDAQ:ZBIO) in a research note issued to investors on Thursday, MarketBeat.com reports. The firm set an “outperform” rating and a $35.00 price target on the stock. Wedbush’s target price suggests a potential upside of 324.24% from the stock’s previous close.

Separately, Guggenheim reiterated a “buy” rating and issued a $45.00 target price on shares of Zenas Biopharma in a report on Wednesday, March 12th.

Zenas Biopharma Stock Performance

Shares of ZBIO opened at $8.25 on Thursday. The stock has a market capitalization of $344.84 million and a PE ratio of -2.32. Zenas Biopharma has a fifty-two week low of $5.83 and a fifty-two week high of $26.25.

About Zenas Biopharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.